Dabrafenib (GSK2118436)

For research use only. Not for use in humans.

目录号：S2807 别名： GSK2118436A 中文名称：达拉菲尼

Dabrafenib (GSK2118436) Chemical Structure

CAS No. 1195765-45-7

Dabrafenib (GSK2118436, GSK2118436A)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1481.39	现货
5mg	RMB 733.64	现货
20mg	RMB 1394.46	现货
50mg	RMB 2235.84	现货
100mg	RMB 3261.37	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献210篇：

Nat Biotechnol, 2021, 10.1038/s41587-021-00837-3

PubMed: 33619394 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Sci Adv, 2021, 7(24)eabg0390

PubMed: 34108213 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1747

PubMed: 33741929 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(8):4421-4440

PubMed: 33849069 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-21-2660

PubMed: 34433654 ( click the link to review the publication )

Cancer Res, 2021, 81(20):5230-5241

PubMed: 34462276 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):107

PubMed: 34419074 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-020-01628-x

PubMed: 33500549 ( click the link to review the publication )

Sci Signal, 2021, 14(682)eabc1648

PubMed: 33975980 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2175

PubMed: 33946525 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3487

PubMed: 34298699 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3635

PubMed: 34298852 ( click the link to review the publication )
Pigment Cell Melanoma Res, 2021, 10.1111/pcmr.13014

PubMed: 34482636 ( click the link to review the publication )

Cell Death Dis, 2021, 12(7):699

PubMed: 34262020 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):85

PubMed: 33446653 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):127

PubMed: 34059622 ( click the link to review the publication )

Cell Death Dis, 2021, 12(9):816

PubMed: 34462421 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Endocr Relat Cancer, 2021, 28(5):311-324

PubMed: 33769310 ( click the link to review the publication )

Clin Sci (Lond), 2021, 135(14):1631-1647

PubMed: 34296750 ( click the link to review the publication )

Neoplasia, 2021, 23(5):539-550

PubMed: 33971465 ( click the link to review the publication )

Biomolecules, 2021, 11(2)153

PubMed: 33503908 ( click the link to review the publication )

Gynecol Oncol, 2021, S0090-8258(21)00648-X

PubMed: 34391578 ( click the link to review the publication )

Front Oncol, 2021, 11:656453

PubMed: 33898322 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(4)1801

PubMed: 33670365 ( click the link to review the publication )

J Proteome Res, 2021, 10.1021/acs.jproteome.1c00331

PubMed: 34343000 ( click the link to review the publication )

Mol Imaging Biol, 2021, 10.1007/s11307-021-01615-y

PubMed: 34101107 ( click the link to review the publication )

Molecules, 2021, 26(8)2141

PubMed: 33917810 ( click the link to review the publication )

Eur J Pharmacol, 2021, 906:174214

PubMed: 34116044 ( click the link to review the publication )

Oncol Lett, 2021, 22(5):745

PubMed: 34539849 ( click the link to review the publication )

Biomed Chromatogr, 2021, e5205

PubMed: 34192355 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)14

PubMed: 33649790 ( click the link to review the publication )

J Physiol Biochem, 2021, 10.1007/s13105-021-00789-x

PubMed: 33587254 ( click the link to review the publication )

Cell Rep Med, 2021, 2(7):100350

PubMed: 34337566 ( click the link to review the publication )

Cancer Immunol Res, 2021, 10.1158/2326-6066.CIR-20-0905

PubMed: 33653716 ( click the link to review the publication )

Mol Carcinog, 2021, 60(3):201-212

PubMed: 33595872 ( click the link to review the publication )
Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202004707

PubMed: 32561648 ( click the link to review the publication )

EMBO Rep, 2020, e50163

PubMed: 33369872 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancer Lett, 2020, 495:135-144

PubMed: 32979462 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2981

PubMed: 33066704 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12932

PubMed: 33000894 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):973

PubMed: 33184267 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):156

PubMed: 32967672 ( click the link to review the publication )

ACS Infect Dis, 2020, acsinfecdis.0c00486

PubMed: 33183004 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Biology (Basel), 2020, 9(8):E218

PubMed: 32785105 ( click the link to review the publication )
ESMO Open, 2020, 5(4):e000707

PubMed: 32817058 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Vet Pathol, 2020, 300985820967449

PubMed: 33205710 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3946

PubMed: 32770055 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31105-31113

PubMed: 33229534 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Acta Neuropathol Commun, 2020, 8(1):139

PubMed: 32811569 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cancer Res, 2019,

PubMed: 31362929 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )
Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )
Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )
Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )
Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )
J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述

Dabrafenib (GSK2118436, GSK2118436A)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

靶点

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

体外研究

Dabrafenib对Raf激酶具有选择性，对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-Raf^V600E激酶，导致ERK磷酸化降低和抑制细胞的增值，在特异性编码突变的B-Raf^V600E的癌细胞中细胞停滞在G1期。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	NYHSR45HU2mwYYPlJGF{e2G7				MXHJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzJJRi\2enZDDCMXJi\iCYNkCwSUBufXSjboSg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCClZXzsd{Bkdy2neIDy[ZN{cW6pIFPER\|M4KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJIJqd3SrbonsZZRm\C2PRVugdJJwfGWrbjDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO\|YYmge4l1cCCLQ{WwJI9nKDBwMECwO{DPxE1?	MlLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2O\|MoRjJ2OUCwOlc{RC:jPh?=
SK-MEL-28	M3zVOGtqdmG\|ZTDBd5NigQ>?		NWPKTJJHOSCq		NIDre25KdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hTVKNIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODRizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyME[3N{c,OjR7MEC2O\|M9N2F-
HepG2	NUi2bpV7U2mwYYPlJGF{e2G7				NYDne41{UW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSgbY4hcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyME[3N{c,OjR7MEC2O\|M9N2F-
COLO205	NX3k[ZU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3mySmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR\|UxKG:oIECuNFA4KM7:TR?=	M1fQWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
HepG2	MoG1SpVv[3Srb36gRZN{[Xl?		NXPGNFRoPDVibXnu	MlyzSG1UVw>?	MXfJcohq[mm2aX;uJI9nKEGua{WgbY4hXEeILXLleIEue3SrbYXsZZRm\CCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBUdWGmMjDwbI9{eGixconsZZRqd25idILlZZRm\CCob4KgOFUhdWmwczDwdolweiC2bzDUS2Yu[mW2YTDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjC2NEBucW6\|IHL5JI9lgXO\|ZYmgZoxwfCC\|Y3HucoVzKGGwYXz5d4l{KHerdHigTWM2OCCxZjCzMlch\|ryP	Mn\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2O\|MoRjJ2OUCwOlc{RC:jPh?=
HFF	NUnwXmN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\GO\|ExKM7:TR?=	MUm3NkBp	Mn3OSG1UVw>?	NGXacWtKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiaIXtZY4hUE[IIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGViQj3SZYYhf2m2aDDJR\|UxKG:oIEOg{txO	M{LFTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
SK-MEL-28	NFnJO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTNb4IyOCEQvF2=	NYTmN5pCPzJiaB?=	M1LS[WROW09?	NGn0SWRKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iU1utUWVNNTJ6IHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yNEOg{txO	NHXxR449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A375P-F11	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVG0ZYpTOTBizszN	MlHnO\|IhcA>?	M4rQWWROW09?	MXHJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hSTN5NWCtSlEyKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPzFizszN	Mkf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MALME-3M	NWX2VJhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYm2cmd5OTBizszN	NYKxV4tWPzJiaB?=	NHjUdXhFVVOR	Mn3JTWM2OD1zIH7N	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
UACC-62	NEPkOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTXXFMyOCEQvF2=	M2jFe\|czKGh?	Mn;KSG1UVw>?	MVXJR\|UxRTFibl2=	NIrmRYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
C32TG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3yxd\|ExKM7:TR?=	MY[3NkBp	NEDZNYtFVVOR	MXLJR\|UxRTFibl2=	NFvmXmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-MEL-1	M4PS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLnNVAh\|ryP	M2HZfFczKGh?	MlvrSG1UVw>?	NFPQR\|NKSzVyPUKgcm0>	MmezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
M14	MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{CzdFExKM7:TR?=	NFPLVZg4OiCq	NHzVbHNFVVOR	MU\JR\|UxRTJibl2=	Mm\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SK-MEL-28	NHTBcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnJNVAh\|ryP	NV;vPI5MPzJiaB?=	MVnEUXNQ	NGezem5KSzVyPUOgcm0>	MoXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A375	NG\jc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7CclQyOCEQvF2=	MWm3NkBp	M4CwbGROW09?	MWPJR\|UxRTRibl2=	NWPwdnZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
DU-4475	MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPSVm8yOCEQvF2=	MmrKO\|IhcA>?	NEDWVJRFVVOR	NWTKU49QUUN3ME21JI5O	NHTIWGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
UACC-257	M3PJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXzWoIyOCEQvF2=	MV:3NkBp	M{PYSmROW09?	NV;SOWd[UUN3ME22JI5O	MnXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Colo 205	M3f1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHTR48yOCEQvF2=	NITM[ZA4OiCq	M2P4S2ROW09?	M{\HT2lEPTB;NzDuUS=>	M2PUcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-MEL-3	NFPxV\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOxNEDPxE1?	MX:3NkBp	MW\EUXNQ	NHnuN2hKSzVyPUegcm0>	NFLZT2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SH-4	M4[3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX:xNEDPxE1?	NIHS[nI4OiCq	M1XEbmROW09?	MkfYTWM2OD16IH7N	NGPXcFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A101D	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmX0NVAh\|ryP	M3roTlczKGh?	Mm\JSG1UVw>?	MmTFTWM2OD17IH7N	NFvBXHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
ES-2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jEVlExKM7:TR?=	NXeyNHRQPzJiaB?=	M1y3c2ROW09?	MXfJR\|UxRTV\|IH7N	NVWzNZZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HT-29	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLZc\|EyOCEQvF2=	MVu3NkBp	NETMSHdFVVOR	NGnPW29KSzVyPU[2JI5O	NWDidVRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW1417	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInsfWkyOCEQvF2=	NF7a[5o4OiCq	NIrWW2pFVVOR	M4T6R2lEPTB;MUW4JI5O	NV3HVXBRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW872	M{P3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7jT2QyOCEQvF2=	M{fMcFczKGh?	M1TlcWROW09?	M4PEfWlEPTB;M{e3JI5O	MlXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
RKO	NGnWW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkGzNVAh\|ryP	NYfGbINWPzJiaB?=	NFnJcnlFVVOR	MnLrTWM2OD1{LkWyNkDPxE1?	Mn7HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A673	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjDXGU3OTBizszN	M3\LWFczKGh?	NEjzXIVFVVOR	Mn7JTWM2OD1zMDFOwG0>	NHGyNpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
GCT	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjqNVAh\|ryP	Moq3O\|IhcA>?	NXLhdmMxTE2VTx?=	M4DJPGlEPTB;MUCg{txO	NGixeGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
WM-115	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\3SFExKM7:TR?=	NX\sdYtWPzJiaB?=	Mm\zSG1UVw>?	MYPJR\|UxRTVibl2=	Ml3MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
YUMAC	M3;ifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfLeVA6OTBizszN	MknFO\|IhcA>?	M{n2TmROW09?	MWHJR\|UxRTVibl2=	M3rYdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OV-90	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TqW\|ExKM7:TR?=	MnXoO\|IhcA>?	M3XmcmROW09?	NGXoVJFKSzVyPUK5JI5O	M1;GZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H508	NHjYOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjJXZo4OTBizszN	NI\oOWc4OiCq	MnexSG1UVw>?	MYLJR\|UxRTFyIN88US=>	MlGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MDA-MB-231	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXS3UFFqOTBizszN	MmfKO\|IhcA>?	MVTEUXNQ	M2q3fGlEPTB;MUCg{txO	MmDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW756	M3fGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17sTFExKM7:TR?=	MX63NkBp	MX3EUXNQ	NIHHdoFKSzVyPUGwJO69VQ>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW-837	M3LQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7HW5UyOCEQvF2=	MlrOO\|IhcA>?	NWrGbZJ7TE2VTx?=	M1n0VWlEPTB;MUCg{txO	NXrHTWNHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
UMUC-3	M3yxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fYdVExKM7:TR?=	NXHQS20yPzJiaB?=	MVLEUXNQ	MofPTWM2OD1zMDFOwG0>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
LS-174T	M3L6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXINIkyOCEQvF2=	Ml3nO\|IhcA>?	MlXwSG1UVw>?	NHLLbIJKSzVyPUGwJO69VQ>?	M4W0WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A549	M37zSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVexNEDPxE1?	M2SxelczKGh?	NYizZmR5TE2VTx?=	NIPYeVlKSzVyPUGwJO69VQ>?	MkG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SHP-77	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILHSlEyOCEQvF2=	M4\nZ\|czKGh?	NXTXc2FVTE2VTx?=	NUXiS\|dwUUN3ME2xNEDPxE1?	M1jz[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW480	NXLlcoxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXYNVAh\|ryP	MUi3NkBp	M4mzZmROW09?	NYfNNJpiUUN3ME2xNEDPxE1?	NV;wWXJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
DLD-1	NHyyd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2foWlExKM7:TR?=	NXTucGdbPzJiaB?=	MWDEUXNQ	M3P4dmlEPTB;MUCg{txO	MoDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HCT-116	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\0R\|ExKM7:TR?=	MXW3NkBp	MV\EUXNQ	NE\6O2ZKSzVyPUGwJO69VQ>?	NGjPXms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H747	M13sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXexNEDPxE1?	MnjnO\|IhcA>?	NXXuTmJbTE2VTx?=	NY\WZoIyUUN3ME2xNEDPxE1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
T-84	NHWxOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYKxNEDPxE1?	NUTaSHZzPzJiaB?=	M1LqVGROW09?	MV;JR\|UxRTFyIN88US=>	NGfHfmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H460	NGOyPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPNNVAh\|ryP	NHLzOZE4OiCq	NX64XGQ3TE2VTx?=	NUS0[lJZUUN3ME2xNEDPxE1?	Mn\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Calu-6	M1;3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXWwT2tmOTBizszN	MnmyO\|IhcA>?	M1:zbGROW09?	MVzJR\|UxRTFyIN88US=>	NXfDW45bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HCC-2998	MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHWNVAh\|ryP	MkHDO\|IhcA>?	NEDHc2xFVVOR	NGrNTGRKSzVyPUGwJO69VQ>?	MoXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
LS1034	M3HSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPlSJgyOCEQvF2=	MkS5O\|IhcA>?	NVvoUpdlTE2VTx?=	NFzLPGRKSzVyPUGwJO69VQ>?	MkjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CHP-212	MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rtb\|ExKM7:TR?=	NXO0Wot7PzJiaB?=	NIqx[IRFVVOR	MoLlTWM2OD1zMDFOwG0>	MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SK-N-AS	Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPWNVAh\|ryP	NV3XfI5tPzJiaB?=	MoLYSG1UVw>?	NFPRfnJKSzVyPUGwJO69VQ>?	NEHDR3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
BFTC-905	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVT5OIZUOTBizszN	M4\lfFczKGh?	MYjEUXNQ	NEjXcppKSzVyPUGwJO69VQ>?	M1jlelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HuT78	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLBemIyOCEQvF2=	Mn;FO\|IhcA>?	MmDUSG1UVw>?	NU\iSYV6UUN3ME21NkBvVQ>?	Mk\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
RPMI-8226	NXHzZWJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fJOlExKM7:TR?=	NXH2WY5MPzJiaB?=	NH7IcFJFVVOR	NVq2NHZFUUN3ME2yOlMhdk1?	M{fORlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
BC-3	M4\pemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV:xNEDPxE1?	NIW2VmE4OiCq	NELGe3ZFVVOR	M1\kZmlEPTB;Mke3JI5O	NFq0OmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
ACHN	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrYOoMyOCEQvF2=	NVnDO4I{PzJiaB?=	NHH5NW5FVVOR	NYPwfFJ5UUN3ME2yPVQhdk1?	NFO0d4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
JRT3-T35	M2TpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXyxNEDPxE1?	NWPJSXcxPzJiaB?=	M1r1PGROW09?	MXHJR\|UxRTJ7NTDuUS=>	M1fQU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-MES-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2SxXlExKM7:TR?=	M2\5d\|czKGh?	MlfwSG1UVw>?	NVTZS\|VuUUN3ME2zNlkhdk1?	NXvDc5N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CESS	M{jDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDKRnEyOCEQvF2=	MVi3NkBp	M3jxWGROW09?	M130RmlEPTB;NEm3JI5O	MmfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
H4	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PPcFExKM7:TR?=	NWD1bXp5PzJiaB?=	NGnUfWhFVVOR	M{iyS2lEPTB;NkG5JI5O	NILkPYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
BC-1	Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTre3o1OTBizszN	M4XPTFczKGh?	MVrEUXNQ	MmqzTWM2OD15MESgcm0>	NGHxZ\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
DB	NWDFS4pFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljlNVAh\|ryP	M3HtOFczKGh?	M{fUcmROW09?	M2HqVWlEPTB;OEezJI5O	M3i0blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
RPMI-6666	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DUS\|ExKM7:TR?=	MXi3NkBp	NFHPXYxFVVOR	NVS4XYNvUUN3ME25Nlghdk1?	NXvib4Q{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
MC/CAR	NUH5dmdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LCdVExKM7:TR?=	MVe3NkBp	M2SyZWROW09?	M2\oUmlEPTB;MT6wNFIh\|ryP	NVTCOYdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SNU-1	NX7Q[JRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVexNEDPxE1?	MUC3NkBp	NHO3N4ZFVVOR	MYnJR\|UxRTFwNUCxJO69VQ>?	M1XoUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CEM/C1	M3LmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\J[JEyOCEQvF2=	M4HzNVczKGh?	MVjEUXNQ	MXPJR\|UxRTFwN{ezJO69VQ>?	M3HkOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
GDM-1	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHSxd2cyOCEQvF2=	Mm\IO\|IhcA>?	NV;uToN7TE2VTx?=	NYfMbnVmUUN3ME2xMlk6PyEQvF2=	NV3iWpo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HT-1080	NYHDVFZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXexNEDPxE1?	M2LOc\|czKGh?	MWjEUXNQ	M{mxd2lEPTB;Mj6wNFQh\|ryP	NVvRbWN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HL-60	NH\OR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYr6NWJJOTBizszN	M3vLU\|czKGh?	MWDEUXNQ	NH73R4VKSzVyPUKuNVc5KM7:TR?=	MlPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
C3A	NYfpeolRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;kclExKM7:TR?=	MmXVO\|IhcA>?	MWrEUXNQ	NIHkW4xKSzVyPUWuOFE1KM7:TR?=	M1nTbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
MES-SA	NWHYWJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPoXnMyOCEQvF2=	MoTrO\|IhcA>?	NITROG1FVVOR	NWTlRo1iUUN3ME22Mlk5QSEQvF2=	MmfnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
22Rv1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjyS2ZXOTBizszN	MoHnO\|IhcA>?	NFrS[WxFVVOR	NHX3T3hKSzVyPUGwJO69VQ>?	MlHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
647-V	NXfKcHpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\HW2tROTBizszN	MUK3NkBp	NXfqd2R1TE2VTx?=	MonNTWM2OD1zMDFOwG0>	NYnDVmQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
786-O	NEL5c2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TydFExKM7:TR?=	M1TXR\|czKGh?	Mo\4SG1UVw>?	M17zbmlEPTB;MUCg{txO	M{SxdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A172	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWixNEDPxE1?	NUHhPYVQPzJiaB?=	MYTEUXNQ	Mn3MTWM2OD1zMDFOwG0>	NHvnZY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A204	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkT6NVAh\|ryP	M3L2[lczKGh?	Ml34SG1UVw>?	MlLYTWM2OD1zMDFOwG0>	NHfjUpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A427	MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVuxNEDPxE1?	NFTrUoI4OiCq	NFnwfWRFVVOR	M1;iWmlEPTB;MUCg{txO	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A431	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Kzd\|ExKM7:TR?=	NV[xbGF5PzJiaB?=	NYLROWhlTE2VTx?=	NILxeVJKSzVyPUGwJO69VQ>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A2780	NXXJbIw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkP6NVAh\|ryP	M1S2NlczKGh?	MnnBSG1UVw>?	MWDJR\|UxRTFyIN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
ARH-77	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV[xNEDPxE1?	NVPWT4ZlPzJiaB?=	M{fDfWROW09?	NFj1V3hKSzVyPUGwJO69VQ>?	NIDme4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Be(2)C	NUfTVmU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxNEDPxE1?	MWC3NkBp	MXXEUXNQ	NV;XPIJKUUN3ME2xNEDPxE1?	M1y3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
BT-20	NY[xXFlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjtdWZVOTBizszN	MVe3NkBp	MmniSG1UVw>?	M{D4[2lEPTB;MUCg{txO	NF7FeHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
BxPc3	M{LpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\uTFExKM7:TR?=	MkPTO\|IhcA>?	NXviVnBRTE2VTx?=	MV;JR\|UxRTFyIN88US=>	NWC1W\|F6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
C-4 I	NYDXTFZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjxc2QyOCEQvF2=	NEDKbZE4OiCq	NEmyNW1FVVOR	NYnKbWdtUUN3ME2xNEDPxE1?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
C33A	MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTPNVAh\|ryP	Mn;yO\|IhcA>?	MYPEUXNQ	MorCTWM2OD1zMDFOwG0>	M3jJbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CAL-27	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7qPWoyOCEQvF2=	MmHiO\|IhcA>?	Mn;lSG1UVw>?	M{PzNGlEPTB;MUCg{txO	NH\DcVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CAL-62	MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVOxNEDPxE1?	NEWzS5M4OiCq	MorUSG1UVw>?	MkXpTWM2OD1zMDFOwG0>	Mn;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Calu-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrGVWEyOCEQvF2=	MnvwO\|IhcA>?	MmTsSG1UVw>?	M3fWTGlEPTB;MUCg{txO	M4rPXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CaOV3	NH\BWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLvNVAh\|ryP	M2DLfVczKGh?	M4ewbWROW09?	Mn7rTWM2OD1zMDFOwG0>	NF[1cHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CGTHW1	M{\zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWOxNEDPxE1?	NXPieolNPzJiaB?=	MoH2SG1UVw>?	Mlr1TWM2OD1zMDFOwG0>	NIDzfVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CHL-1	M3Po[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[0UFExKM7:TR?=	MkKzO\|IhcA>?	NGGxVItFVVOR	M2r2VGlEPTB;MUCg{txO	NEPZW4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Colo320DM	M3;MZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPTOnYyOTBizszN	NUXZPHMzPzJiaB?=	Mnm0SG1UVw>?	NYKybJNyUUN3ME2xNEDPxE1?	NF;ubVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Colo704	M1XWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUGxNEDPxE1?	M1nudlczKGh?	MV;EUXNQ	MmLjTWM2OD1zMDFOwG0>	M1PsO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
COR-L23	M{npT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV31e3c5OTBizszN	MWG3NkBp	Mlr2SG1UVw>?	MkXyTWM2OD1zMDFOwG0>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CRO-AP2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWCxNEDPxE1?	M4\QS\|czKGh?	NWm2PXZ2TE2VTx?=	NFPFfZhKSzVyPUGwJO69VQ>?	NH;hc5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Daudi	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3TNFgyOCEQvF2=	NHPo[oY4OiCq	MojSSG1UVw>?	MYHJR\|UxRTFyIN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
DOTC 24510	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUexNEDPxE1?	M1ruTlczKGh?	M{jkWWROW09?	M4DHVWlEPTB;MUCg{txO	M1zVfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DU-145	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;FNVAh\|ryP	NVHrRVA{PzJiaB?=	NWj5NJk{TE2VTx?=	NIX3ZpNKSzVyPUGwJO69VQ>?	NFj1c5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
EB-3	M1vK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPwNVAh\|ryP	NV\ofWR[PzJiaB?=	NGnzRnpFVVOR	NEPNbGlKSzVyPUGwJO69VQ>?	MmewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
EFM-19	NHHzfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Xhc\|ExKM7:TR?=	NYe1flhzPzJiaB?=	MXLEUXNQ	MoPTTWM2OD1zMDFOwG0>	M{H5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
EKVX	NF\GdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXONVAh\|ryP	MWm3NkBp	M1\uVmROW09?	M2TSXGlEPTB;MUCg{txO	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
FaDu	NWfwOWVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPscXQyOCEQvF2=	MlTwO\|IhcA>?	MXvEUXNQ	M3LDbmlEPTB;MUCg{txO	M1zje\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
G401	NWTUe\|FPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfrNVAh\|ryP	NID1bZY4OiCq	MkTxSG1UVw>?	MYLJR\|UxRTFyIN88US=>	NUf4XoV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HCC-70	M1rFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mor3NVAh\|ryP	M{LuTlczKGh?	M2[2OWROW09?	M2TWRmlEPTB;MUCg{txO	M1nUbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HCC-1954	M2fUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1T2b\|ExKM7:TR?=	MXq3NkBp	MonuSG1UVw>?	NYDrXo9GUUN3ME2xNEDPxE1?	M2\qPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
Hela	M{HTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUixNEDPxE1?	M{HCXFczKGh?	MUXEUXNQ	NHP5TnlKSzVyPUGwJO69VQ>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Hep3B	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVP4WXpCOTBizszN	MnrHO\|IhcA>?	NFTjUmFFVVOR	MmnoTWM2OD1zMDFOwG0>	NUmzdGc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HMCB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7kPXB4OTBizszN	Moj0O\|IhcA>?	MlLDSG1UVw>?	M2jieGlEPTB;MUCg{txO	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HN5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvZN\|YyOCEQvF2=	Mk\VO\|IhcA>?	M3zMT2ROW09?	NEj4eYxKSzVyPUGwJO69VQ>?	NWn3T3pNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HOS	NYXoU5BYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI[yUHAyOCEQvF2=	NUC2dlFsPzJiaB?=	NWG5N2pCTE2VTx?=	M2jTOWlEPTB;MUCg{txO	NHPJenQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HPAF-II	NGTxenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYexNEDPxE1?	Mn7hO\|IhcA>?	M1r3NWROW09?	M{DXWGlEPTB;MUCg{txO	NX3US2ZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Hs746.T	M{LQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;3WlExKM7:TR?=	MVe3NkBp	NX\ufVlzTE2VTx?=	MorTTWM2OD1zMDFOwG0>	NFm3[VI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HT	NE\4PHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33sWVExKM7:TR?=	MnG5O\|IhcA>?	MoLQSG1UVw>?	MmLYTWM2OD1zMDFOwG0>	MlPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HT-3	NVnNbXFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUSxNEDPxE1?	MUe3NkBp	MlXnSG1UVw>?	MVTJR\|UxRTFyIN88US=>	MnnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HuNS-1	NUm1WIRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK3fGsyOCEQvF2=	NUHTeHB6PzJiaB?=	M{LZ[2ROW09?	M1PJd2lEPTB;MUCg{txO	MmKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
IGROV1	M3\VNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\LZ\|BvOTBizszN	NXXU[3o6PzJiaB?=	M37D[WROW09?	NYLuTGpXUUN3ME2xNEDPxE1?	M4O0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
J82	MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXT2S5ZQOTBizszN	NIfJOms4OiCq	Ml3sSG1UVw>?	MnvUTWM2OD1zMDFOwG0>	NWKxWFkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
JM1	NVX3b2NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PMO\|ExKM7:TR?=	MWO3NkBp	MWXEUXNQ	MUPJR\|UxRTFyIN88US=>	NXPFOmVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Kato III	NY\FTmJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHm2dWwyOCEQvF2=	MmfpO\|IhcA>?	M{fle2ROW09?	M2PTZ2lEPTB;MUCg{txO	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
KHOS-240S	M1fsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlSyNVAh\|ryP	MnO1O\|IhcA>?	NHzNNVNFVVOR	MXjJR\|UxRTFyIN88US=>	NX3JUI9ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
KM-12	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHDNVAh\|ryP	NXvPTGZ3PzJiaB?=	MXzEUXNQ	Mk\aTWM2OD1zMDFOwG0>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
KPL-1	M131Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXWxNEDPxE1?	MkH0O\|IhcA>?	M1TX[2ROW09?	NVL6RZh7UUN3ME2xNEDPxE1?	M{frVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
KYSE-30	M33WUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;Db2E3OTBizszN	M{XLNFczKGh?	NWfWXmw4TE2VTx?=	M4n3bGlEPTB;MUCg{txO	MoqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
LNCaP	NF6wWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrn[Iw6OTBizszN	M{HNT\|czKGh?	Mn3iSG1UVw>?	Ml\STWM2OD1zMDFOwG0>	Ml\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MCF-7	NUHvU3hMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVmxNEDPxE1?	M{nzfFczKGh?	NGDnU4ZFVVOR	MUDJR\|UxRTFyIN88US=>	Mn7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MC-IXC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFS2NHMyOCEQvF2=	M3fF[\|czKGh?	Mom2SG1UVw>?	NVy2PZRQUUN3ME2xNEDPxE1?	M{e0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
MDA-MB-175 VII	NWP0U2wyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\ySlQyOCEQvF2=	NEDCWpE4OiCq	Mlu0SG1UVw>?	NYLFVohPUUN3ME2xNEDPxE1?	MnH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MDA-MB-468	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV[xNEDPxE1?	MkTKO\|IhcA>?	NXPkU3c{TE2VTx?=	MYfJR\|UxRTFyIN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
MiaPaCa	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3y5flExKM7:TR?=	MX63NkBp	M{\sS2ROW09?	NGTlR3ZKSzVyPUGwJO69VQ>?	NUjtZoxlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Molt-4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkm5NVAh\|ryP	NHP2ToU4OiCq	MkexSG1UVw>?	NYnHN\|N2UUN3ME2xNEDPxE1?	M3LsT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-ADR/RES	NH3yUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXHS40yOCEQvF2=	M4i2eVczKGh?	M3;UTGROW09?	MmXnTWM2OD1zMDFOwG0>	M4PrZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H69	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLJS5UyOCEQvF2=	Mnu1O\|IhcA>?	NWDsVIpLTE2VTx?=	MUDJR\|UxRTFyIN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H82	NYq0W\|VKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvsU2YyOCEQvF2=	NHTqNpQ4OiCq	Mn7tSG1UVw>?	MoD4TWM2OD1zMDFOwG0>	NF\DNmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-N87	NIf3UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\LNVAh\|ryP	M{njNFczKGh?	NUPndYpiTE2VTx?=	MlfSTWM2OD1zMDFOwG0>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H146	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvo[GMyOCEQvF2=	M{fXZ\|czKGh?	M1zPV2ROW09?	NUTk[4xVUUN3ME2xNEDPxE1?	MnHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H157	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjkZYUyOCEQvF2=	MlnHO\|IhcA>?	NGW1OXBFVVOR	NWG4WVIxUUN3ME2xNEDPxE1?	NWHafWF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H187	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUn4NFIzOTBizszN	NXy5R5NxPzJiaB?=	MVPEUXNQ	NF;ZcG5KSzVyPUGwJO69VQ>?	MmLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H209	NYO3cIFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\BSoFMOTBizszN	NFvTPYo4OiCq	NUPufI1[TE2VTx?=	M1rLRmlEPTB;MUCg{txO	NHzJZpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H226	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXexNEDPxE1?	NILVe4o4OiCq	M2fDXGROW09?	MWnJR\|UxRTFyIN88US=>	NUDwenhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H292	M3vQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXuwVVRvOTBizszN	MUG3NkBp	M2nXbmROW09?	NVrReYUyUUN3ME2xNEDPxE1?	M{TR[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H322	NX\o[pk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\kenMyOTBizszN	MUW3NkBp	MkfHSG1UVw>?	NFjoV2JKSzVyPUGwJO69VQ>?	NGmyOXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H358	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mln6NVAh\|ryP	MUO3NkBp	NWrTXXhRTE2VTx?=	MVvJR\|UxRTFyIN88US=>	NX3H[lh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H520	NUfCdGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jsUVExKM7:TR?=	NVyz[mRuPzJiaB?=	NWHXOXhmTE2VTx?=	NFridHdKSzVyPUGwJO69VQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H526	M2XEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYexNEDPxE1?	MoDOO\|IhcA>?	NYXPWHlUTE2VTx?=	NFK2T4VKSzVyPUGwJO69VQ>?	M1jtN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H630	M4LDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrWNVAh\|ryP	M3rq[\|czKGh?	MUDEUXNQ	NXq0eYU4UUN3ME2xNEDPxE1?	M1LPV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H661	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;1V4MyOCEQvF2=	MnTsO\|IhcA>?	MkjpSG1UVw>?	NYPmNm5mUUN3ME2xNEDPxE1?	MmmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H716	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXmxNEDPxE1?	M3[4TVczKGh?	MX;EUXNQ	MkO3TWM2OD1zMDFOwG0>	NXu2U213RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H1563	M3jIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYSxNEDPxE1?	NV\mVGwzPzJiaB?=	MV\EUXNQ	M17ZSmlEPTB;MUCg{txO	M2DRc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H1792	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPHXodjOTBizszN	NVzL[JJqPzJiaB?=	MWTEUXNQ	MnjjTWM2OD1zMDFOwG0>	NVjaNlVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H2030	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnCT\|AyOCEQvF2=	MXi3NkBp	NXzrPXRoTE2VTx?=	NX7SeYpVUUN3ME2xNEDPxE1?	M1TzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H2052	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXx[pNmOTBizszN	NVK5cmdbPzJiaB?=	NUnqeWtvTE2VTx?=	MXHJR\|UxRTFyIN88US=>	Ml\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H2122	M1v1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Ky[\|ExKM7:TR?=	NWi3N3MyPzJiaB?=	MUfEUXNQ	M{PhdmlEPTB;MUCg{txO	NIXTe2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H2228	M3z2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\QcVExKM7:TR?=	MVi3NkBp	M4TJU2ROW09?	M1LDdWlEPTB;MUCg{txO	M2HpSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OE-19	M2Ls[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2i5N\|ExKM7:TR?=	NFPX[IY4OiCq	MmH5SG1UVw>?	NH:2ToxKSzVyPUGwJO69VQ>?	NVLN[2dbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
OE-21	M{nETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj2NWgyOCEQvF2=	M1vY[FczKGh?	MXTEUXNQ	MVjJR\|UxRTFyIN88US=>	M2DETVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OE-33	NVXxOoFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVWzOotWOTBizszN	NWXUWXFsPzJiaB?=	MVfEUXNQ	MoXuTWM2OD1zMDFOwG0>	M2DyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OVCAR-3	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXFN3JoOTBizszN	M2LLOlczKGh?	M{\pfGROW09?	NInQcHRKSzVyPUGwJO69VQ>?	M4HWZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OVCAR-4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvQO4YyOCEQvF2=	M4i2VlczKGh?	NVzFe\|ZQTE2VTx?=	MkTITWM2OD1zMDFOwG0>	M3HNZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OVCAR-5	NYGyemlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfYT3QyOCEQvF2=	MmTsO\|IhcA>?	MYfEUXNQ	MoPhTWM2OD1zMDFOwG0>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
P3HR-1	NEH4[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLKNVAh\|ryP	MVi3NkBp	M2XYc2ROW09?	MWTJR\|UxRTFyIN88US=>	Ml3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
PC-3	NFPKRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfCNooyOCEQvF2=	MkjEO\|IhcA>?	NYT6XY96TE2VTx?=	NYm5[nBSUUN3ME2xNEDPxE1?	NHjYelU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Raji	M1nhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HCN\|ExKM7:TR?=	MmH4O\|IhcA>?	NYfKN21UTE2VTx?=	NYDMNlBJUUN3ME2xNEDPxE1?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
RD	NV74V\|NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLFNVAh\|ryP	NXu0bJp6PzJiaB?=	NGjh[2dFVVOR	MWHJR\|UxRTFyIN88US=>	MoHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
RD-ES	M1\BSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLmNVAh\|ryP	NXnVdYdbPzJiaB?=	NV\NV4U2TE2VTx?=	M{PudGlEPTB;MUCg{txO	NHHmfJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
RL	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLIelcyOCEQvF2=	M3jGNlczKGh?	MVvEUXNQ	M{LKZWlEPTB;MUCg{txO	M2PWZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SaOS2	MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYOxNEDPxE1?	MkjQO\|IhcA>?	MX7EUXNQ	NHni[nhKSzVyPUGwJO69VQ>?	Ml\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCC-9	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fXclExKM7:TR?=	M1LKXlczKGh?	M2PXTWROW09?	M13OSmlEPTB;MUCg{txO	MkfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCC-12	NIC0WVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DN[\|ExKM7:TR?=	MkPPO\|IhcA>?	NHnwSplFVVOR	M1r5cGlEPTB;MUCg{txO	MknWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCC-13	Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;xVGFxOTBizszN	M3rhSlczKGh?	NUXOelZ5TE2VTx?=	Mm\JTWM2OD1zMDFOwG0>	MoraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCC-15	NFm0WppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LpXVExKM7:TR?=	NF;JWlA4OiCq	M2DxZWROW09?	MlnsTWM2OD1zMDFOwG0>	Mn7NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCC-25	NUPZTlJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDFNVAh\|ryP	NYPvNVJtPzJiaB?=	NEH6PXdFVVOR	NGrOZYZKSzVyPUGwJO69VQ>?	NV;rcY9wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SCLC-3	Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4O4elExKM7:TR?=	MXW3NkBp	MkjBSG1UVw>?	MYrJR\|UxRTFyIN88US=>	NEDoe5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SF-268	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPxRWQyOCEQvF2=	MUC3NkBp	MUDEUXNQ	MoPnTWM2OD1zMDFOwG0>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SF-295	NUjNUHRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrTU44yOCEQvF2=	MmPyO\|IhcA>?	MVXEUXNQ	MXTJR\|UxRTFyIN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SJRH30	M3exOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fWNFExKM7:TR?=	NH7aTWg4OiCq	MX3EUXNQ	NFXTU3lKSzVyPUGwJO69VQ>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-BR-3	NH7Q[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rTSFExKM7:TR?=	MkPjO\|IhcA>?	MX3EUXNQ	M2rFNGlEPTB;MUCg{txO	M1n6WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-LMS-1	NGPVVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\CZWoyOCEQvF2=	NGfNcIY4OiCq	M2nWWWROW09?	MlHlTWM2OD1zMDFOwG0>	NG\PPZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-N-DZ	M4Ww[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTEWXptOTBizszN	M2S3UlczKGh?	NX7jSHBITE2VTx?=	NXXVelhoUUN3ME2xNEDPxE1?	M3LMblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-N-F1	NF3SV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrNNVAh\|ryP	NEToSpo4OiCq	NICyUWZFVVOR	Ml3pTWM2OD1zMDFOwG0>	NX7kcoRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SKOV-3	NUL4d3lmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXmxNEDPxE1?	NFrwPW04OiCq	Moj1SG1UVw>?	NVrw[3hjUUN3ME2xNEDPxE1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-UT-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLqNVAh\|ryP	MkLDO\|IhcA>?	MlLiSG1UVw>?	M1PCZmlEPTB;MUCg{txO	NIfndFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SN12C	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[yblExKM7:TR?=	MkfYO\|IhcA>?	MkPISG1UVw>?	MXXJR\|UxRTFyIN88US=>	NHfEbnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SNB-19	M{jPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoP6NVAh\|ryP	NXKze3pbPzJiaB?=	NYfyNlJITE2VTx?=	MXLJR\|UxRTFyIN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SNU-5	NISzfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYqzVWZSOTBizszN	M1LPSlczKGh?	NUS0bpRwTE2VTx?=	Ml[2TWM2OD1zMDFOwG0>	NFvHeHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SNU-16	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\VbFNSOTBizszN	M3\kSlczKGh?	NUXhRoFRTE2VTx?=	MWjJR\|UxRTFyIN88US=>	NWPaUIxwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SNU-398	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInlcmEyOCEQvF2=	M2W2e\|czKGh?	NGLXVHpFVVOR	M17lUmlEPTB;MUCg{txO	NVHpN2IxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SNU-449	M4G3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXyxNEDPxE1?	NXr2epdHPzJiaB?=	MUDEUXNQ	Mnq5TWM2OD1zMDFOwG0>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SR	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVSxNEDPxE1?	MlTwO\|IhcA>?	M37jeWROW09?	M3LDcWlEPTB;MUCg{txO	M2L6dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
ST486	NVX6UXh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUmxNEDPxE1?	MlHJO\|IhcA>?	MUTEUXNQ	Mlq1TWM2OD1zMDFOwG0>	M2DOXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW579	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLjNVAh\|ryP	MV23NkBp	MkPISG1UVw>?	NWTKU5lqUUN3ME2xNEDPxE1?	M1rBWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW684	M4Pwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfENVAh\|ryP	M2\DTlczKGh?	MnOwSG1UVw>?	NHnUXlFKSzVyPUGwJO69VQ>?	M2n4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW-780	M3jTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofsNVAh\|ryP	NFPPR\|M4OiCq	NH3xWm9FVVOR	MlzyTWM2OD1zMDFOwG0>	NWHEWYZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW900	Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnQTJhzOTBizszN	M3jXNFczKGh?	M2HnSWROW09?	NYfwS5BrUUN3ME2xNEDPxE1?	NHzmOIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SW1088	NHfYdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DVc\|ExKM7:TR?=	NXXpboZWPzJiaB?=	MWfEUXNQ	Ml7HTWM2OD1zMDFOwG0>	NEWySVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SW1463	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYOxNEDPxE1?	MmjnO\|IhcA>?	NYPtc25STE2VTx?=	MmS1TWM2OD1zMDFOwG0>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW1990	M4j1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXLNVAh\|ryP	NEDwUWo4OiCq	NFr3OJdFVVOR	MVvJR\|UxRTFyIN88US=>	NWOyO\|NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
T47D	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVixNEDPxE1?	MX23NkBp	MUTEUXNQ	MXTJR\|UxRTFyIN88US=>	NX\WbZB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
TE381.T	M1TZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV6xNEDPxE1?	MmLRO\|IhcA>?	NXj2c4tSTE2VTx?=	M2X2UWlEPTB;MUCg{txO	NGjTc3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
TK-10	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDVd4oyOCEQvF2=	NIThb2k4OiCq	NXzj[5pvTE2VTx?=	MUXJR\|UxRTFyIN88US=>	NGL5c\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
U2OS	M2TYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[5NVAh\|ryP	NFTsO2k4OiCq	NHvub3dFVVOR	MmCzTWM2OD1zMDFOwG0>	NU\IdoFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
U251	NEDQNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojxNVAh\|ryP	MkjmO\|IhcA>?	NYDj[oF[TE2VTx?=	M{fRTGlEPTB;MUCg{txO	NWPscZI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
UACC-812	NGqzUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3xZpo{OTBizszN	MUe3NkBp	MkXVSG1UVw>?	NWLV[2lVUUN3ME2xNEDPxE1?	Mmf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
YAPC	M2HZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYOxNEDPxE1?	MmTlO\|IhcA>?	MVLEUXNQ	MV\JR\|UxRTFyIN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
ZR-75-1	M4TkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;xRVExKM7:TR?=	MV63NkBp	NILROpJFVVOR	NFPGdVBKSzVyPUGwJO69VQ>?	M3\wRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A375	M2T5bmZ2dmO2aX;uJIF{e2G7	MXexMlIh\|ryP	M4DwUlQhcA>?	M4r1d2ROW09?	MWDJcohq[mm2aX;uJI9nKHCqb4PwbI9zgWyjdHnvckBw\iCPRVusJGVTUyxiYX7kJHM3WA>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN6OUS3NUc,OjJ\|OEm0O\|E9N2F-
YUSIT1	Mkj4SpVv[3Srb36gZZN{[Xl?			MYXEUXNQ	MV\y[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0>	MlOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|OEm0O\|EoRjJ{M{i5OFcyRC:jPh?=
MeWo	NV;i[4Z[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M3LYNmROW09?	MoHmTWM2OCB;IEm4O{BvVQ>?	MkLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUi1NlQoRjJ4MEG4OVI1RC:jPh?=
WiDr	NVGwdYVyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NUHvfZhrTE2VTx?=	NVTsTVJoUUN3MDC9JFc3KG6P	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjBzOEWyOEc,OjZyMUi1NlQ9N2F-
Colo-205	MYHGeY5kfGmxbjDhd5NigQ>?	NYrHfGNnOSEQvF2=	MoGwOEBl	Mnq0SG1UVw>?	NGOyUWtKdmS3Y3XkJIEhcGmpaHz5JINwdXCjcnHicIUh[2:vcHHjeIlwdiCyaHXuc5R6eGV?	Mn\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|OEGxOVIoRjJ3M{ixNVUzRC:jPh?=
RBW-1	NYS4SHk3TnWwY4Tpc44h[XO\|YYm=	Mmi5NUDPxE1?		NVXVR5BGTE2VTx?=	MWjOc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	M{\LSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEi1OlkxLz5{NEi4OVY6ODxxYU6=
RBO-1	M3P1OmZ2dmO2aX;uJIF{e2G7	MYKxJO69VQ>?		MYDEUXNQ	M2D2WWlvcGmkaYTpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	NH3aOVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OVY6OCd-MkS4PFU3QTB:L3G+
RBO-2	MWTGeY5kfGmxbjDhd5NigQ>?	MkjONUDPxE1?		MVHEUXNQ	MYDJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	NV7TbW9HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFU3QTBpPkK0PFg2PjlyPD;hQi=>
RBOW	MnXxSpVv[3Srb36gZZN{[Xl?	NGPrZlUyKM7:TR?=		M1\ic2ROW09?	NWXP[HJQUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25?	NVHsTHFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFU3QTBpPkK0PFg2PjlyPD;hQi=>
M257	M3;wS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWWxXYJoOTByIH7N	NEXk[IM4OiCq		M2T3dGRw\XNibn;0JIlvcGmkaYSgdJJwdGmoZYLheIlwdiCxZjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?=	Mnv5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUe0OFYoRjJ\|M{G3OFQ3RC:jPh?=
LCP	NYDpOIJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWxNFAhdk1?	MkTNO\|IhcA>?		MUHJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhVEOSIHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCUIH31eIFvfGG2aX;u	NVrVOVdtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVc1PDZpPkKzN\|E4PDR4PD;hQi=>
WM266	NIewS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnXUIF4OTByIH7N	NFv3R2g4OiCq		M3K3RWlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>?	NGnCbWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxO\|Q1Pid-MkOzNVc1PDZ:L3G+
M257	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvONVAxKG6P	MoTYO\|IhcA>?		MY\Ec4V{KG6xdDDpcohq[mm2IFXST\|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTUK1O{Bk\WyuIHjhdoJwfXKrbnege4lt\CC2eYDlJGJTSUZ?	Ml3IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUe0OFYoRjJ\|M{G3OFQ3RC:jPh?=
LCP	M3nSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvzbmNpOTByIH7N	M3rsb\|czKGh?		NIjWeGlKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUGNRKGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBTKG23dHHueIF1cW:w	MlLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUe0OFYoRjJ\|M{G3OFQ3RC:jPh?=
WM266	NWr3[4dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3WNVAxKG6P	MoLtO\|IhcA>?		NV\tW2N5UW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJHdOOjZ4IHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCGIH31eIFvfGG2aX;u	NUPkXIg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVc1PDZpPkKzN\|E4PDR4PD;hQi=>
A375	NX72Z2ZZSlKDRjDjc41x\XSrdHn2[UBjcW6maX7nJIF{e2G7		NX3STo03OTVibXnu		NVWwN45IUUN3MDC9JFAvODB4IN88US=>	NVS4Z41zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
A375	Mo[1SpVv[3Srb36gZZN{[Xl?		MWC3NkBp		MV3JR\|UxKD1iMD6wNVEh\|ryP	MkfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
A375	NFm3VGFCWkGIIHPvcZBmfGm2aY\lJIJqdmSrbnegZZN{[Xl?		MmTPNVUhdWmw		M{f3fGlEPTBiPTCwMlAzPiEQvF2=	NYXIWXNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
A375	MmXiR3JCTiClb33w[ZRqfGm4ZTDibY5lcW6pIHHzd4F6		NXexNIFXOTVibXnu		NV\VRXp[UUN3MDC9JFAvOTVizszN	M37sTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[1PFA1Lz5{NUm2OVgxPDxxYU6=
HCT116	MWHGeY5kfGmxbjDhd5NigQ>?				MW\JR\|UxKD1iNT64PEDPxE1?	M2LVXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[1PFA1Lz5{NUm2OVgxPDxxYU6=
A375	NULCNItwTnWwY4Tpc44h[XO\|YYm=		MVqxJIg>		MmHNTWM2OCB;IECuNFAyKM7:TR?=	NYf5Z4RbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFU3PzJpPkK3NFg2Pjd{PD;hQi=>
MIAPaCa2	M2fYR2Z2dmO2aX;uJIF{e2G7		MnfFNUBp		NX7JVlRkTUN3MDC9JFAvPTJ7IN88US=>	NETEWVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C4OVY4Oid-MkewPFU3PzJ:L3G+
A375	NE\Cem1HfW6ldHnvckBie3OjeR?=				MmnNTWM2OCB;IECuNFA1KM7:TR?=	NGnNTW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2NVgzPyd-Mkm0OlE5Ojd:L3G+
SK-MEL-28	NHK2fIFEgXSxdH;4bYNqfHliYYPzZZk>		M1jhelczKGh?		NWrHWG42UUN3MDC9JFAvODR\|IN88US=>	NGDCXZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2NVgzPyd-Mkm0OlE5Ojd:L3G+
Sf9	NV;Zb4NpTnWwY4Tpc44h[XO\|YYm=		M3fu[FYxKG2rbh?=		MlfOTWM2OCB;IECuNFA6KM7:TR?=	Ml7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxN\|coRjJ5N{e0NVM4RC:jPh?=
SK-MEL-28	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MofpOFghcA>?		MmGwS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2suVUWOLUK4JINmdGy\|IHjhdoJwemmwZzDCVmFHKFZ4MEDFJI12fGGwdDDt[YF{fXKnZDDh[pRmeiB2ODDodpMhemW\|YYr1dolvKGG\|c3H5	M{LVbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVM4Lz5{N{e3OFE{PzxxYU6=
SK-MEL-28	NVnVeo1bT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEX5Spc1QCCq		M1TzR2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yPEBk\WyuczDoZZJjd3KrbnegRnJCTiCYNkCwSUBufXSjboSgdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IHnydoFlcWG2aX;uJI9nKDFwMUOgb3cwdTJiVW[tcIlocHRiZn;yJFUhdWmwczDt[YF{fXKnZDDh[pRmeiB2ODDodpMhemW\|YYr1dolvKGG\|c3H5	NWf3ToY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOzdpPkK3O\|c1OTN5PD;hQi=>
SK-MEL-28	M4HQZWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4nueVQ5KGh?		MYTDfZRwe3SjdHnjJIFkfGm4aYT5JIlvKGi3bXHuJHNMNU2HTD2yPEBk\WyuczDoZZJjd3KrbnegRnJCTiCYNkCwSUBufXSjboSgZZQhOSCjbnSgN\|AhfU1ibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJJJme2G8dYLpckBie3OjeR?=	M4XHc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVM4Lz5{N{e3OFE{PzxxYU6=
DAOY	Mn7rVJJqdWG{eTDzZ5Jm\W5iYYPzZZk>				NUPUT3BKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	NHe2fII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NUTJT2tVWHKrbXHyfUB{[3KnZX6gZZN{[Xl?				NV\rVXk2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NXfKR3pERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MX\Qdolu[XK7IIPjdoVmdiCjc4PhfS=>				NFX5eplyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NIrUdpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

体内研究

Dabrafenib（口服）抑制B-RafV600E突变的黑色素瘤（A375P）的生长，在免疫受损小鼠中皮下注射结肠癌（Colo205），Dabrafenib（口服）同样能抑制肿瘤生长。 ^[1]

参考文献

溶解度 (25°C)

体外	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+45% PEG 300+2% Tween 80+ddH2O	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dabrafenib (GSK2118436) SDF

分子量	519.56
化学式	C₂₃H₂₀F₃N₅O₂S₂
CAS号	1195765-45-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	GSK2118436A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04961619	Not yet recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma	Novartis Pharmaceuticals\|Novartis	October 20 2021	--
NCT04547946	Not yet recruiting	Drug: dabrafenib + trametinib	Malignant Melanoma	Novartis Pharmaceuticals\|Novartis	September 30 2021	--
NCT04775095	Recruiting	--	Non Small Cell Lung Cancer\|BRAF V600 Mutation	Intergroupe Francophone de Cancerologie Thoracique\|Novartis	March 8 2021	--
NCT04666272	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma	Novartis Pharmaceuticals\|Novartis	December 31 2020	--

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

泛Raf抑制剂

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA批准的Raf抑制剂

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
最新的Raf抑制剂

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

研究领域

产品类型

定制您的化合物库

Dabrafenib (GSK2118436)

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献210篇：

产品安全说明书

Raf抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dabrafenib (GSK2118436) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

相关Raf产品